Factors associated with hepcidin-25 levels in maintenance hemodialysis patients

被引:1
|
作者
Savkovic, Miljan [1 ]
Simic-Ogrizovic, Sanja [2 ,3 ]
Dopsaj, Violeta [1 ,4 ]
机构
[1] Clin Ctr Serbia, Ctr Med Biochem, Belgrade, Serbia
[2] Gen Hosp Medigrp, Belgrade, Serbia
[3] Univ Banja Luka, Fac Med, Banja Luka, Bosnia & Herceg
[4] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia
关键词
dialysis; erythropoiesis‐ stimulating agents; hepcidin; inflammation; intravenous iron; CHRONIC KIDNEY-DISEASE; SERUM HEPCIDIN-25; IRON; ERYTHROPOIETIN; FERRITIN; ANEMIA; RESISTANCE; INFLAMMATION; PROHEPCIDIN; REGULATOR;
D O I
10.1111/1744-9987.13617
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to investigate the factors that are independently associated with hepcidin-25 and its relationship with doses of erythropoiesis-stimulating agents (ESAs) and intravenous iron in stable maintenance hemodialysis patients (smHD) stratified by ESAs administration. In 103 adult smHD (ESAs therapy (N = 64) and ESAs-free (N = 39)), median values of biologically active hepcidin-25 (chemiluminescent direct ELISA assay) and ferritin levels were significantly higher whereas red blood cell count, hemoglobin, and hematocrit values were lower in ESAs therapy compared to ESAs-free group (P < .001, for all). Our results suggest that ESAs-independent smHD exhibit supposedly normal hepcidin-25 levels and preserved iron homeostasis, with a lower degree of anemia. The results of our multivariable model indicate that hepcidin-25 levels are independently and positively associated with iron stores and inflammation, and inversely with active erythropoiesis, regardless of ESAs administration. Maintenance ESAs and the intravenous iron dose were not related to hepcidin-25 levels.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 50 条
  • [1] Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients?
    Kali, Alaaddin
    Yayar, Ozlem
    Erdogan, Bulent
    Eser, Baris
    Buyukbakkal, Mehmet
    Ercan, Zafer
    Merhametsiz, Ozgur
    Haspulat, Ayhan
    Gok Oguz, Ebru
    Canbakan, Basol
    Ayli, Mehmet D.
    [J]. HEMODIALYSIS INTERNATIONAL, 2016, 20 (02) : 191 - 197
  • [2] Serum Hepcidin-25 and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis
    Zou, Lu-Xi
    Sun, Ling
    Hua, Rui-Xue
    Wu, Yu
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 3153 - 3162
  • [3] HEPCIDIN-25 IS RELATED TO CARDIOVASCULAR EVENTS IN CHRONIC HEMODIALYSIS PATIENTS
    Van der Weerd, Neelke C.
    Grooteman, Muriel P. C.
    Bots, M. L.
    Van den Dorpel, Marinus A.
    Den Hoedt, Claire
    Nube, Menso J.
    Wetzels, J. F. M.
    Swinkels, Dorine W.
    Blankestijn, P. J.
    Ter Wee, Pieter M.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 246 - 246
  • [4] Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients
    Kato, Akihiko
    Tsuji, Takayuki
    Luo, Jinghui
    Sakao, Yukitoshi
    Yasuda, Hideo
    Hishida, Akira
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (01) : 115 - 121
  • [5] Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients?
    Bratescu, Lavinia O.
    Barsan, Liliana
    Munteanu, Dan
    Stancu, Simona
    Mircescu, Gabriel
    [J]. JOURNAL OF RENAL NUTRITION, 2010, 20 (05) : S77 - S83
  • [6] SERUM HEPCIDIN-25 LEVEL; IS IT RELATED TO CARDIOVASCULAR MORTALITY IN HEMODIALYSIS PATIENTS?
    Yayar, Ozlem
    Eser, Baris
    Oguz, Ebru Gok
    Merhametsiz, Ozgur
    Gursoy, Guner Karaveli
    Atilgan, Gokhan
    Canbakan, Basol
    Ayli, Deniz
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [7] HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients
    Valenti, Luca
    Girelli, Domenico
    Valenti, Giovanni Francesco
    Castagna, Annalisa
    Como, Giovanna
    Campostrini, Natascia
    Rametta, Raffaela
    Dongiovanni, Paola
    Messa, Piergiorgio
    Fargion, Silvia
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (08): : 1331 - 1337
  • [8] HIGH SERUM LEVELS OF HEPCIDIN-25 AND MORTALITY IN CANCER PATIENTS WITH KIDNEY DISEASE
    Masaki, Hara
    Minoru, Ando
    Hirohiko, Nokiba
    Taku, Morito
    Ken, Tsuchiya
    Kosaku, Nitta
    [J]. NEPHROLOGY, 2014, 19 : 74 - 74
  • [9] HEPCIDIN-25 AND TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS ARE INDEPENDENTLY RELATED WITH ERYTHROPOIESIS IN CHRONIC HEMODIALYSIS PATIENTS
    Belo, Luis
    Rocha, Susana
    Valente, Maria Joao
    Coimbra, Susana
    Catarino, Cristina
    Bronze-da-Rocha, Elsa
    Carvalho, Marcia
    Rocha-Pereira, Petronila
    do Sameiro-Faria, Maria
    Oliveira, Jose Gerardo
    Madureira, Jose
    Fernandes, Joao Carlos
    Miranda, Vasco
    Santos-Silva, Alice
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [10] Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
    van der Weerd, Neelke C.
    Grooteman, Muriel P. C.
    Bots, Michiel L.
    van den Dorpel, Marinus A.
    den Hoedt, Claire H.
    Mazairac, Albert H. A.
    Nube, Menso J.
    Penne, E. Lars
    Gaillard, Carlo A.
    Wetzels, Jack F. M.
    Wiegerinck, Erwin T.
    Swinkels, Dorine W.
    Blankestijn, Peter J.
    ter Wee, Piet M.
    [J]. PLOS ONE, 2012, 7 (07):